# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.31) b...
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.